Efficacy of a selective phosphodiesterase 4 inhibitor in patients with asthma–COPD overlap syndrome
https://doi.org/10.18093/0869-0189-2015-25-3-327-332
Abstract
The purpose of the study was to investigate effects of roflumilast on the level of control, systemic inflammation markers, general and mucosal humoral anti-endotoxin immunity in patients with asthma–COPD overlap syndrome (ACOS). Methods. Forty patients with ACOS were involved. All the patients were treated with a standard therapy. Of them, 20 patients received roflumilast additionally during 1 month. Clinical parameters were analyzed using ACQ Elizabeth Juniper questionnaire, mMRC scale and spirometry. Anti-endotoxin antibodies A, M, G classes and C-reactive protein were measured by ELISA. Results. Additional administration of roflumilast significantly improved control of the disease, reduced systemic inflammation and improved mucosal anti-endotoxin immunity in patients ACOS with neutrophil inflammation. Six-month follow-up showed that the effect prolonged in 15.8% of the patients. Conclusion. Efficacy and duration of effects of roflumilast in ACOS patients requires further research.
About the Authors
V. A. Beloglazov
State Institution “S.I.Georgievskiy Crimea State Medical University”: 5 / 7, Lenina av., Simferopol', 295006, Crimea Republic, Russia
Russian Federation
Russian Federation
MD, Professor, Head of Department of Internal Medicine N2; State Institution “S.I.Georgievskiy Crimea State Medical University”; tel. / fax: +38 (0652) 247-530; тел.: +38 (0652) 37-35-30;
Yu. O. Popenko
State Institution “S.I.Georgievskiy Crimea State Medical University”: 5 / 7, Lenina av., Simferopol', 295006, Crimea Republic, Russia
Russian Federation
Russian Federation
PhD student at the Department of Internal Medicine N2; State Institution “S.I.Georgievskiy Crimea State Medical University”
A. I. Gordienko
State Institution “S.I.Georgievskiy Crimea State Medical University”: 5 / 7, Lenina av., Simferopol', 295006, Crimea Republic, Russia
Russian Federation
Russian Federation
PhD in Biology, Head of Clinical and Immunological Laboratory of the Central Scientific Laboratory; State Institution “S.I.Georgievskiy Crimea State Medical University”; tel.: +38 (0652) 554-896;
References
1. Global initiative for asthma: Diagnosis of diseases of chronic airflow limitation: asthma, COPD and asthma-COPD overlap syndrome. Режим доступа: http:// www.ginasthma.org
2. Global initiative for chronic obstructive lung disease diagnosis: Diagnosis of diseases of chronic airflow limitation: asthma, COPD and asthma-COPD overlap syndrome. Режим доступа: http:// www. goldcopd.org
3. Белевский А.С. Синдром перекреста бронхиальной астмы и хронической обструктивной болезни легких (по материалам совместного документа рабочих групп экспертов GINA и GOLD). Практическая пульмонология. 2014; 2: 12–19.
4. Qiu Y., Zhu J., Bandi V. et al. Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma. Thorax. 2007; 62: 475–482.
5. Gauvreau G.M., Boulet L.-P., Schmid-Wirlitsch C. et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir. Res. 2011; 12: 140. http://respiratory-research.com/content/12/1/140
6. Calverley P.M., Rabe K.F., Goehring U.M. et al. M2-124 and M2-125 study groups: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374: 685–694.
7. Simpson J.L., Grissell T.V., Douwes J. et al. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax. 2007; 62: 211–218.
8. Fabbri L.M., Calverley P.M., Izquierdo-Alonso J.L. et al. M2-127 and M2-128 study groups: Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374: 695–703.
9. Яшина Л.А. Симпозіум. Рофлуміласт: терапія ХОЗЛ на максимальній глубині. Український пульмонологічний журнал. 2011; 2: 23–25.
10. Гордієнко А.I. Бiлоглазов В.О., Бакова А.А. Високочутливий імуноферментний метод кількісного визначення вмісту С-реактивного білка в крові: Інформаційний лист про нововведення в системі охорони здоров'я № 139. Киев: Укрмедпатентiнформ; 2010.
11. Гордиенко А.И. Использование твердофазного иммуноферментного анализа для определения общего и антиэндотоксинового секреторного IgA человека. Таврический медико-биологический вестник. 2009; 3 (47): 82–89.
12. Paggiaro P.L., Chanez P., Holz O. et al. Sputum induction. Eur. Respir. J. 2002; 22 (Suppl. 37): 3–8.
13. Global initiative for chronic obstructive lung disease: Global strategy for diagnosis management and prevention of chronic obstructive pulmonary disease (update 2010). Режим доступа: http:// www.goldcopd.org
14. Lu S., Lui N., Dass B. et al. Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma. Respir. Med. 2009; 103 (3): 342–347.
15. Barnes P.J. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br. J. Pharmacol. 2006; 148: 245–254.
16. Grootendorst D.C., Gauw S.A., Verhoosel R. M. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007; 62 (12): 1081–1087.
17. Синопальников А.И., Романовских А.Г. Рофлумиласт: новые возможности фармакотерапии ХОБЛ. Русский медицинский журнал. 2012; 12: 1339–1343.
18. Currie C.G., McCallum K., Poxton I.R. Mucosal and systemic antibody responses to the lipopolysaccharide of Escherichia coli O157 in health and disease. Med. Microbiol. 2001; 50: 345–354.
Review
For citations:
Beloglazov V.A., Popenko Yu.O., Gordienko A.I. Efficacy of a selective phosphodiesterase 4 inhibitor in patients with asthma–COPD overlap syndrome. PULMONOLOGIYA. 2015;25(3):327-332. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-3-327-332
Views:
1513
Email this article 